AGT and Myocardial fibrosis: Conversely, the treatment of 4-HCH significantly improved cardiac systolic dysfunction (decreased EF and FS), suppressed cardiac hypertrophy (increase of heart size, HW/BW, and HW/TL ratios, cross-sectional area of myocytes), and myocardial fibrosis compared with those observed in vehicle-treated mice following Ang II infusion (Fig. 4c–f).